Third Santorini conference - From human genetic variations to prediction of risks and responses to d

Venue: Nomikos Conference Center-Thira

Location: Santorini, Greece

Event Date/Time: Sep 29, 2006 End Date/Time: Oct 02, 2006
Report as Spam


After our successful Santorini meetings, the one in 2002 and which was started with Jean Dausset notes on predictive medicine with HLA system and the last one in 2004 which was opened by D.C. Wallace introduction on populations mitochondrial gene variations, we would like to continue in 2006 the global genomic and proteomics laboratory medicine approach with the use of molecular markers for the prediction of individual risks, the prevention of population risks, the diagnostic of multifactorial diseases and the follow up of life habits changes and drug therapies.

“The existence in every human being of a vast array of attributes which are potentially measurable (whether by present methods or not), and often uncorrelated mathematically, makes quite tenable the hypothesis that practically every human being is a deviate in some respects.”
Roger J. Williams – Biochemical individuality 1956. Fifty years ago!

There exists now a real possibility to measure the “vast array of attributes”. The genome is sequenced, the proteom is in detailed investigation, the population variation including the healthy ones has to be studied in great details with such genetic and proteomic markers to better know, after R.J. Williams and the Cheraskin Onion model (1970), the environments and genetic effects.
That is the important epidemiological phase which should now connect genetics and proteomics variations to future health or illness.
For such population studies we need biobanks to translate the data collected on long periods into predictive or personalized medicine.
Based on these information, our general and specific objectives for the 2006 Colloquium are as follow:

Bridging The Gap Between Genomics And Proteomics
To communicate the state of molecular markers (genetics, transcriptomics and proteomics) in multifactorial diseases particularly in cardiovascular, inflammatory, cancer and neurological diseases.

To define the use of these markers in the prediction of risks, diseases, drug responses and drug side effects for an individual (personalized medicine) or for a subgroup or a population. Is it translational medicine?

To address how emerging molecular laboratory technologies could be combined to imaging for a global health assessment and therapeutical intervention using also information technologies.

To better understand the molecular basis of clinical responses to drugs in defined molecular based subgroups of diseases.

To increase knowledge of environmental effects including nutrition on all these molecular markers

To link the omics markers to metabolite networks (metabolomics, lipidomics, …)

To test functional significance of genes polymorphisms and protein isoforms in the metabolic systems using gene networks

To define the real future of multivariate biology using systems biology.

To use blood cells as tissular information and using them as sentinels in all these strategies.

Bridging discovery to the citizens
To use genotype information to predict likelihood of beneficial changes.

To select a subset of genotypes important for prediction of risks or drug efficacy and for according adverse reactions.

To validate the potential of molecular markers based on chip – based - DNA and protein microarrays which focus on the translational application for personalized prediction and prevention, for bedside usage for public health populations’ studies and for clinical trials.

To include in any step the preanalytical variation in healthy and sick people which is usually often forgotten before any use of sophisticated new technology.

To better know age effects on all these processes and to emphasize positive outcomes on health i.e. longevity. To discover new markers linked to age related effects

To discuss patients acceptability and ethics.

To respond to most of these objectives, we believe that biobanks will be a great tool to use.